| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | Anja Krause | |
| Stefan Worgall | |||
| Anurag Sharma | |||
| P2860 | cites work | PcrV immunization enhances survival of burned Pseudomonas aeruginosa-infected mice | Q24548633 |
| The failed HIV Merck vaccine study: a step back or a launching point for future vaccine development? | Q24652185 | ||
| Effects of monoclonal anti-PcrV antibody on Pseudomonas aeruginosa-induced acute lung injury in a rat model | Q24797978 | ||
| A new adenovirus based vaccine vector expressing an Eimeria tenella derived TLR agonist improves cellular immune responses to an antigenic target | Q27333475 | ||
| Crystal structure of Pseudomonas aeruginosa PAK pilin suggests a main-chain-dominated mode of receptor binding | Q27622776 | ||
| Structure of a pilin monomer from Pseudomonas aeruginosa: implications for the assembly of pili | Q27631112 | ||
| Animal Protection and Structural Studies of a Consensus Sequence Vaccine Targeting the Receptor Binding Domain of the Type IV Pilus of Pseudomonas aeruginosa | Q27648780 | ||
| Development of a preventive vaccine for Ebola virus infection in primates | Q28140401 | ||
| Cutting edge: bacterial flagellin activates basolaterally expressed TLR5 to induce epithelial proinflammatory gene expression | Q28211358 | ||
| Vaccines and immunotherapy against Pseudomonas aeruginosa | Q28266964 | ||
| N-Acetyl-L-galactosaminuronic acid as an epitope common to the O-polysaccharides of Pseudomonas aeruginosa serotype A and H (Homma) recognized by a protective human monoclonal antibody | Q28323473 | ||
| The AlgT-dependent transcriptional regulator AmrZ (AlgZ) inhibits flagellum biosynthesis in mucoid, nonmotile Pseudomonas aeruginosa cystic fibrosis isolates | Q28492672 | ||
| The Pseudomonas aeruginosa flagellar cap protein, FliD, is responsible for mucin adhesion | Q28493024 | ||
| Outer Membrane Proteins of Pseudomonas aeruginosa Serotype Strains | Q28493204 | ||
| Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial | Q28972526 | ||
| Development of adenoviral-vector-based pandemic influenza vaccine against antigenically distinct human H5N1 strains in mice. | Q30352927 | ||
| Mucosal vaccination with a multivalent, live-attenuated vaccine induces multifactorial immunity against Pseudomonas aeruginosa acute lung infection | Q30430870 | ||
| Oral vaccination of BALB/c mice with Salmonella enterica serovar Typhimurium expressing Pseudomonas aeruginosa O antigen promotes increased survival in an acute fatal pneumonia model | Q30435195 | ||
| IL-17 is a critical component of vaccine-induced protection against lung infection by lipopolysaccharide-heterologous strains of Pseudomonas aeruginosa. | Q30438358 | ||
| Intranasal immunization with heterologously expressed polysaccharide protects against multiple Pseudomonas aeruginosa infections | Q30443179 | ||
| Protection against fatal Pseudomonas aeruginosa pneumonia in mice after nasal immunization with a live, attenuated aroA deletion mutant | Q30453151 | ||
| Experimental studies of the pathogenesis of infections due to Pseudomonas aeruginosa: immunization using divalent flagella preparations | Q68953062 | ||
| Safety and immunogenicity of a polyvalent Pseudomonas aeruginosa O-polysaccharide-toxin A vaccine in humans | Q69258261 | ||
| Type-specific immunity in pseudomonas diseases | Q69371188 | ||
| Serologic and protective cross-reactivity of antisera to Pseudomonas aeruginosa extracellular slime glycolipoprotein | Q70325957 | ||
| Effect of Pseudomonas aeruginosa proteases on human leukocyte phagocytosis and bactericidal activity | Q70334522 | ||
| Characterization of the human immune response to a Pseudomonas aeruginosa O-polysaccharide-toxin A conjugate vaccine | Q70389743 | ||
| Characterization of the human immune response to a polysaccharide vaccine from Pseudomonas aeruginosa | Q70445499 | ||
| Immunization of burned patients against Pseudomonas aeruginosa infection at Safdarjang Hospital, New Delhi | Q70460605 | ||
| In vivo activity of proteases of Pseudomonas aeruginosa in a rat model | Q70480660 | ||
| Immunoprophylaxis against klebsiella and pseudomonas aeruginosa infections. The Federal Hyperimmune Immunoglobulin Trial Study Group | Q71434752 | ||
| Immunity to respiratory Pseudomonas aeruginosa infection: the role of gut-derived T helper cells and immune serum | Q71596206 | ||
| Parenteral application of a Pseudomonas aeruginosa flagella vaccine elicits specific anti-flagella antibodies in the airways of healthy individuals | Q72111709 | ||
| Immunization of noncolonized cystic fibrosis patients against Pseudomonas aeruginosa | Q72389027 | ||
| Controlled trial of Pseudomonas immunoglobulin and vaccine in burn patients | Q72441078 | ||
| A role for CD4+ T cells from orally immunized rats in enhanced clearance of Pseudomonas aeruginosa from the lung | Q72463197 | ||
| Immunochemical characterization of the mucoid exopolysaccharide of Pseudomonas aeruginosa | Q72779862 | ||
| Comparison of two immunization schedules for a Pseudomonas aeruginosa outer membrane proteins vaccine in burn patients | Q73343105 | ||
| Analysis of immunization with DNA encoding Pseudomonas aeruginosa exotoxin A | Q73367913 | ||
| Chimeric animal and plant viruses expressing epitopes of outer membrane protein F as a combined vaccine against Pseudomonas aeruginosa lung infection | Q73572386 | ||
| Immunization with a Pseudomonas aeruginosa elastase peptide reduces severity of experimental lung infections due to P. aeruginosa Or Burkholderia cepacia | Q73819146 | ||
| Pharmacokinetics, tolerability, and preliminary efficacy of human anti-Pseudomonas aeruginosa monoclonal antibodies in pneumonia and burn infection patients | Q73919367 | ||
| Efficacies of alkaline protease, elastase and exotoxin A toxoid vaccines against gut-derived Pseudomonas aeruginosa sepsis in mice | Q74502674 | ||
| A recombinant hybrid outer membrane protein for vaccination against Pseudomonas aeruginosa | Q77295193 | ||
| Human immune response to a Pseudomonas aeruginosa outer membrane protein vaccine | Q78164014 | ||
| Synthesis and characterization of Pseudomonas aeruginosa alginate-tetanus toxoid conjugate | Q79149639 | ||
| Mechanisms of antimicrobial resistance in bacteria | Q79823685 | ||
| Blocking of the TLR5 activation domain hampers protective potential of flagellin DNA vaccine | Q80582293 | ||
| Passive anti-PcrV treatment protects burned mice against Pseudomonas aeruginosa challenge | Q81345573 | ||
| Multi-valent human monoclonal antibody preparation against Pseudomonas aeruginosa derived from transgenic mice containing human immunoglobulin loci is protective against fatal pseudomonas sepsis caused by multiple serotypes | Q81661579 | ||
| Advantages of a synthetic peptide immunogen over a protein immunogen in the development of an anti-pilus vaccine for Pseudomonas aeruginosa | Q37373738 | ||
| HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis | Q37413781 | ||
| The immune system vs. Pseudomonas aeruginosa biofilms | Q37767747 | ||
| Adaptation of Pseudomonas aeruginosa during persistence in the cystic fibrosis lung | Q37799900 | ||
| Delivery of antigens by viral vectors for vaccination. | Q38029626 | ||
| Pseudomonas aeruginosa antigens as potential vaccines | Q38340469 | ||
| Interaction of the receptor binding domains of Pseudomonas aeruginosa pili strains PAK, PAO, KB7 and P1 to a cross-reactive antibody and receptor analog: implications for synthetic vaccine design | Q38347527 | ||
| Low mortality in burned patients in a Pseudomonas vaccine trial | Q39502555 | ||
| Effect of antiflagellar human monoclonal antibody on gut-derived Pseudomonas aeruginosa sepsis in mice | Q39506398 | ||
| Controlled trials of a polyvalent pseudomonas vaccine in burns | Q39574016 | ||
| Therapeutic effect of immunization with OEP, protease toxoid and elastase toxoid on corneal ulcers in mice due to Pseudomonas aeruginosa infection | Q39608253 | ||
| Effectiveness of immunization with single and multi-component vaccines prepared from a common antigen (OEP), protease and elastase toxoids of Pseudomonas aeruginosa on protection against hemorrhagic pneumonia in mink due to P. aeruginosa | Q39629607 | ||
| Proposal of an international standard for the infraspecific serologic classification of Pseudomonas aeruginosa | Q39678264 | ||
| Effects of a human antiflagellar monoclonal antibody in combination with antibiotics on Pseudomonas aeruginosa infection | Q39874977 | ||
| Synthetic peptides representing epitopes of outer membrane protein F of Pseudomonas aeruginosa that elicit antibodies reactive with whole cells of heterologous immunotype strains of P. aeruginosa | Q40147770 | ||
| A protective human monoclonal antibody directed to the outer core region of Pseudomonas aeruginosa lipopolysaccharide | Q40149450 | ||
| Synthesis and characterization of a Pseudomonas aeruginosa alginate-toxin A conjugate vaccine | Q40149473 | ||
| Inhibitory activity on bacterial motility and in vivo protective activity of human monoclonal antibodies against flagella of Pseudomonas aeruginosa | Q40149884 | ||
| Inhibition of human lymphocyte proliferation and cleavage of interleukin-2 by Pseudomonas aeruginosa proteases | Q40158244 | ||
| Immunization with a Pseudomonas aeruginosa immunotype 5 O polysaccharide-toxin A conjugate vaccine: effect of a booster dose on antibody levels in humans | Q40158359 | ||
| Immunochemical and biochemical analysis of the polyvalent Pseudomonas aeruginosa vaccine PEV. | Q40172509 | ||
| Surface localization of Pseudomonas aeruginosa outer membrane porin protein F by using monoclonal antibodies | Q40182140 | ||
| New immunotype schema for Pseudomonas aeruginosa based on protective antigens | Q40287481 | ||
| Effector mechanisms of intestinally induced immunity to Pseudomonas aeruginosa in the rat lung: role of neutrophils and leukotriene B4 | Q40374025 | ||
| Pulmonary immunity to Pseudomonas aeruginosa in intestinally immunized rats roles of alveolar macrophages, tumor necrosis factor alpha, and interleukin-1 alpha. | Q40376445 | ||
| Recognition of host immune activation by Pseudomonas aeruginosa | Q40391951 | ||
| Pseudomonas aeruginosa flagellin and alginate elicit very distinct gene expression patterns in airway epithelial cells: implications for cystic fibrosis disease | Q40501945 | ||
| Antibiotic therapy for chronic infection of pseudomonas in the lung | Q40897885 | ||
| Overproduction of the CFTR R domain leads to increased levels of asialoGM1 and increased Pseudomonas aeruginosa binding by epithelial cells | Q41017727 | ||
| Chimeric influenza viruses incorporating epitopes of outer membrane protein F as a vaccine against pulmonary infection with Pseudomonas aeruginosa. | Q41128804 | ||
| A polyreactive human anti-lipid A monoclonal antibody having cross reactivity to polysaccharide portions of Pseudomonas aeruginosa lipopolysaccharides | Q41200525 | ||
| Effects of elastase, protease and common antigen (OEP) from Pseudomonas aeruginosa on protection against burns in mice | Q41379731 | ||
| Formulation and immunogenicity of a potential multivalent type III secretion system-based protein vaccine | Q41432317 | ||
| Generation and characterization of a protective monoclonal antibody to Pseudomonas aeruginosa PcrV. | Q41471489 | ||
| Active and passive immunization with the Pseudomonas V antigen protects against type III intoxication and lung injury | Q41483182 | ||
| Rationale for development of immunotherapies that target mucoid Pseudomonas aeruginosa infection in cystic fibrosis patients. | Q41650958 | ||
| Production and Characterization of Human Monoclonal Antibody Recognizing the N-Terminal Residues ofPseudomonas aeruginosaExotoxin A | Q41690481 | ||
| Human monoclonal antibodies to Pseudomonas aeruginosa type-specific lipopolysaccharides, toxin A and Klebsiella capsular polysaccharides | Q41748131 | ||
| A human-human hybridoma secreting anti-Pseudomonas aeruginosa exotoxin-A monoclonal antibody with highly potent neutralizing activity | Q41757535 | ||
| Avidity of anti-P aeruginosa antibodies during chronic infection in patients with cystic fibrosis | Q41811499 | ||
| A clinical trial of i.v. tetravalent hyperimmune Pseudomonas globulin G in burned patients | Q42029228 | ||
| Assessment of pulmonary antibodies with induced sputum and bronchoalveolar lavage induced by nasal vaccination against Pseudomonas aeruginosa: a clinical phase I/II study | Q42134586 | ||
| A nontoxic Pseudomonas exotoxin A induces active immunity and passive protective antibody against Pseudomonas exotoxin A intoxication | Q42810737 | ||
| Mice immunized with DNA encoding a modified Pseudomonas aeruginosa exotoxin A develop protective immunity against exotoxin intoxication | Q42832929 | ||
| An engineered human antibody fab fragment specific for Pseudomonas aeruginosa PcrV antigen has potent antibacterial activity | Q42906503 | ||
| Study of protective properties of recombinant atoxic form of exotoxin A and recombinant outer membrane protein F of Pseudomonas aeruginosa | Q43064988 | ||
| A fusion protein vaccine containing OprF epitope 8, OprI, and type A and B flagellins promotes enhanced clearance of nonmucoid Pseudomonas aeruginosa. | Q43121719 | ||
| Pseudomonas aeruginosa-specific IgG1 and IgG2 subclasses in enhancement of pulmonary clearance following passive immunisation in the rat. | Q43414816 | ||
| Affinity Constants of Naturally Acquired and Vaccine-Induced Anti-Pseudomonas aeruginosa Antibodies in Healthy Adults and Cystic Fibrosis Patients | Q43420176 | ||
| Pseudomonas aeruginosa vaccine in cancer patients | Q43456413 | ||
| OprF/I-vaccinated sera inhibit binding of human interferon-gamma to Pseudomonas aeruginosa | Q43516725 | ||
| Safety and immunogenicity of an intranasal Pseudomonas aeruginosa hybrid outer membrane protein F-I vaccine in human volunteers | Q43546816 | ||
| Enhancement of the protective efficacy of an oprF DNA vaccine against Pseudomonas aeruginosa | Q43609149 | ||
| Pharmacokinetics of an IgM human monoclonal antibody against Pseudomonas aeruginosa in nonseptic patients | Q43720908 | ||
| Efficient antigen gene transduction using Arg-Gly-Asp fiber-mutant adenovirus vectors can potentiate antitumor vaccine efficacy and maturation of murine dendritic cells | Q43787471 | ||
| Anti-Pseudomonas aeruginosa serotype O11 LPS immunoglobulin M monoclonal antibody panobacumab (KBPA101) confers protection in a murine model of acute lung infection | Q44121558 | ||
| Recombinant OprF-OprI as a vaccine against Pseudomonas aeruginosa infections | Q44254430 | ||
| Immunological Control of Pseudomonas Infection in Burn Patients: A Clinical Evaluation | Q44358012 | ||
| Recombinant protein composed of Pseudomonas exotoxin A, outer membrane proteins I and F as vaccine against P. aeruginosa infection | Q44560435 | ||
| Use of a Pseudomonas Aeruginosa vaccine in pateints with acute leukemia and cystic fibrosis | Q44595256 | ||
| Protective activity of an intravenous immune globulin (human) enriched in antibody against lipopolysaccharide antigens of Pseudomonas aeruginosa | Q44694972 | ||
| Immunization of burn-patients with a Pseudomonas aeruginosa outer membrane protein vaccine elicits antibodies with protective efficacy | Q44999397 | ||
| Human monoclonal antibodies to Pseudomonas aeruginosa alginate that protect against infection by both mucoid and nonmucoid strains. | Q45115153 | ||
| Construction and characterization of a live, attenuated aroA deletion mutant of Pseudomonas aeruginosa as a candidate intranasal vaccine | Q30453226 | ||
| Glycosylation of Pseudomonas aeruginosa 1244 pilin: glycan substrate specificity | Q31116468 | ||
| Expression and testing of Pseudomonas aeruginosa vaccine candidate proteins prepared with the Caulobacter crescentus S-layer protein expression system | Q31863748 | ||
| rBCG induces strong antigen-specific T cell responses in rhesus macaques in a prime-boost setting with an adenovirus 35 tuberculosis vaccine vector | Q33386020 | ||
| Active immunization using exotoxin A confers protection against Pseudomonas aeruginosa infection in a mouse burn model | Q33404470 | ||
| Protection against Pseudomonas aeruginosa lung infection in mice by recombinant OprF-pulsed dendritic cell immunization | Q33523622 | ||
| Dual-function vaccine for Pseudomonas aeruginosa: characterization of chimeric exotoxin A-pilin protein | Q33553144 | ||
| Evaluation of flagella and flagellin of Pseudomonas aeruginosa as vaccines. | Q33613907 | ||
| Protection against P. aeruginosa with an adenovirus vector containing an OprF epitope in the capsid. | Q33727055 | ||
| Complex serology and immune response of mice to variant high-molecular-weight O polysaccharides isolated from Pseudomonas aeruginosa serogroup O2 strains | Q33757770 | ||
| A chimeric influenza virus expressing an epitope of outer membrane protein F of Pseudomonas aeruginosa affords protection against challenge with P. aeruginosa in a murine model of chronic pulmonary infection | Q33760042 | ||
| Live attenuated Salmonella: a paradigm of mucosal vaccines. | Q33784947 | ||
| CAR-dependent and CAR-independent pathways of adenovirus vector-mediated gene transfer and expression in human fibroblasts. | Q33842878 | ||
| Immunogenicity of a Salmonella typhimurium aroA aroD vaccine expressing a nontoxic domain of Clostridium difficile toxin A. | Q33866797 | ||
| Preclinical in vitro and in vivo characterization of the fully human monoclonal IgM antibody KBPA101 specific for Pseudomonas aeruginosa serotype IATS-O11. | Q33876419 | ||
| Safety and immunogenicity of a Pseudomonas aeruginosa hybrid outer membrane protein F-I vaccine in human volunteers. | Q34000731 | ||
| Preparation and preclinical evaluation of a novel liposomal complete-core lipopolysaccharide vaccine | Q34004972 | ||
| Protection against Pseudomonas aeruginosa chronic lung infection in mice by genetic immunization against outer membrane protein F (OprF) of P. aeruginosa | Q34007482 | ||
| Replacing adenoviral vector HVR1 with a malaria B cell epitope improves immunogenicity and circumvents preexisting immunity to adenovirus in mice | Q34162092 | ||
| Research Article: Synthetic Peptide Vaccine Development: Designing Dual Epitopes into a Single Pilin Peptide Immunogen Generates Antibody Cross‐reactivity between Two Strains of Pseudomonas aeruginosa | Q34172641 | ||
| Influence of pilin glycosylation on Pseudomonas aeruginosa 1244 pilus function | Q34194800 | ||
| Novel adenovirus vector-based vaccines for HIV-1. | Q34257640 | ||
| Safety and immunogenicity of an oral inactivated whole-cell pseudomonas aeruginosa vaccine administered to healthy human subjects | Q34334155 | ||
| A live-attenuated Pseudomonas aeruginosa vaccine elicits outer membrane protein-specific active and passive protection against corneal infection. | Q34334168 | ||
| Generation of neutralizing activity against human immunodeficiency virus type 1 in serum by antibody gene transfer | Q34344205 | ||
| Immunogenic and antigenic properties of a heptavalent high-molecular-weight O-polysaccharide vaccine derived from Pseudomonas aeruginosa. | Q34535624 | ||
| Human immune response to Pseudomonas aeruginosa mucoid exopolysaccharide (alginate) vaccine. | Q34537794 | ||
| Inhibition of bacterial motility with human antiflagellar monoclonal antibodies attenuates Pseudomonas aeruginosa-induced pneumonia in the immunocompetent rat. | Q34543905 | ||
| Epitopes expressed in different adenovirus capsid proteins induce different levels of epitope-specific immunity | Q34648154 | ||
| Protective anti-Pseudomonas aeruginosa humoral and cellular mucosal immunity by AdC7-mediated expression of the P. aeruginosa protein OprF. | Q34701517 | ||
| In vitro and in vivo activity of polyclonal and monoclonal human immunoglobulins G, M, and A against Pseudomonas aeruginosa lipopolysaccharide | Q35089066 | ||
| Proteolytic inactivation of cytokines by Pseudomonas aeruginosa | Q35104384 | ||
| Construction and characterization of a Pseudomonas aeruginosa mucoid exopolysaccharide-alginate conjugate vaccine. | Q35106317 | ||
| Generation and characterization of murine antiflagellum monoclonal antibodies that are protective against lethal challenge with Pseudomonas aeruginosa. | Q35108367 | ||
| Prospective, controlled study of a polyvalent pseudomonas vaccine in cystic fibrosis--three year results | Q35118667 | ||
| Synthetic peptide vaccine and antibody therapeutic development: prevention and treatment of Pseudomonas aeruginosa | Q35136110 | ||
| Progress toward the development of a bacterial vaccine vector that induces high-titer long-lived broadly neutralizing antibodies against HIV-1. | Q35165404 | ||
| Characterization of monoclonal antibody B7, which neutralizes the cytotoxicity of Pseudomonas aeruginosa exotoxin A. | Q35228212 | ||
| Protection of immunocompromised mice against lethal infection with Pseudomonas aeruginosa by active or passive immunization with recombinant P. aeruginosa outer membrane protein F and outer membrane protein I fusion proteins | Q35410420 | ||
| Immunogenicity against human papillomavirus type 16 virus-like particles is strongly enhanced by the PhoPc phenotype in Salmonella enterica serovar Typhimurium | Q35550509 | ||
| Safety and immunogenicity of a Pseudomonas aeruginosa O-polysaccharide toxin A conjugate vaccine in humans | Q35575338 | ||
| Pseudomonas immunotherapy: a historical overview | Q35710136 | ||
| Differentiation of Pseudomonas aeruginosa pili based on sequence and B-cell epitope analyses | Q35772376 | ||
| Therapeutic effects of a human antiflagella monoclonal antibody in a neutropenic murine model of Pseudomonas aeruginosa pneumonia | Q35808176 | ||
| A double-blind randomized placebo-controlled phase III study of a Pseudomonas aeruginosa flagella vaccine in cystic fibrosis patients | Q35864978 | ||
| Passive antibody therapy for infectious diseases | Q35889582 | ||
| Adenovirus vector-based vaccines for human immunodeficiency virus type 1. | Q36068094 | ||
| Adenovirus-based genetic vaccines for biodefense | Q36068099 | ||
| Pseudomonas aeruginosa: the potential to immunise against infection | Q36194089 | ||
| Protective immunity to pseudomonas aeruginosa induced with a capsid-modified adenovirus expressing P. aeruginosa OprF. | Q36315185 | ||
| Development of nonhuman adenoviruses as vaccine vectors | Q36317264 | ||
| Flagellar preparations from Pseudomonas aeruginosa: animal protection studies | Q36434214 | ||
| Immunization with a Pseudomonas aeruginosa 1244 pilin provides O-antigen-specific protection | Q36539114 | ||
| Polysaccharide antigens of Pseudomonas aeruginosa | Q36597493 | ||
| New serotypes of adenoviral vectors | Q36641334 | ||
| Modification to the capsid of the adenovirus vector that enhances dendritic cell infection and transgene-specific cellular immune responses | Q36954135 | ||
| Protection of immunosuppressed mice against infection with Pseudomonas aeruginosa by recombinant P. aeruginosa lipoprotein I and lipoprotein I-specific monoclonal antibodies | Q36961991 | ||
| Activation of a dendritic cell-T cell axis by Ad5 immune complexes creates an improved environment for replication of HIV in T cells | Q36979919 | ||
| Protection against experimental Pseudomonas aeruginosa infection by recombinant P. aeruginosa lipoprotein I expressed in Escherichia coli | Q36985634 | ||
| Human monoclonal antibodies that protect mice against challenge with Pseudomonas aeruginosa | Q36997788 | ||
| Pseudomonas aeruginosa alkaline protease degrades human gamma interferon and inhibits its bioactivity | Q37000857 | ||
| Outer membrane protein F preparation of Pseudomonas aeruginosa as a vaccine against chronic pulmonary infection with heterologous immunotype strains in a rat model | Q37003335 | ||
| Pseudomonas aeruginosa adhesins for tracheobronchial mucin | Q37017100 | ||
| Inhibition of human natural killer cell activity by Pseudomonas aeruginosa alkaline protease and elastase | Q37017904 | ||
| Replication-defective adenovirus vectors with multiple deletions do not induce measurable vector-specific T cells in human trials | Q37204584 | ||
| Pharmacokinetics and safety profile of the human anti-Pseudomonas aeruginosa serotype O11 immunoglobulin M monoclonal antibody KBPA-101 in healthy volunteers | Q37274670 | ||
| Baseline Ad5 serostatus does not predict Ad5 HIV vaccine-induced expansion of adenovirus-specific CD4+ T cells | Q37295542 | ||
| Adenovirus-specific immunity after immunization with an Ad5 HIV-1 vaccine candidate in humans | Q37372794 | ||
| High level expression of a human rabies virus-neutralizing monoclonal antibody by a rhabdovirus-based vector. | Q45737525 | ||
| Circumventing the immune response to adenovirus-mediated gene therapy | Q45879012 | ||
| Protective effects of affinity-purified antibody and truncated vaccines against Pseudomonas aeruginosa V-antigen in neutropenic mice. | Q45980499 | ||
| Therapy with anti-flagellin A monoclonal antibody limits Pseudomonas aeruginosa invasiveness in a mouse burn wound sepsis model. | Q46296428 | ||
| Therapeutic administration of anti-PcrV F(ab')(2) in sepsis associated with Pseudomonas aeruginosa. | Q46818181 | ||
| Octavalent Pseudomonas aeruginosa O-polysaccharide-toxin A conjugate vaccine | Q46834988 | ||
| Rapid/sustained anti-anthrax passive immunity mediated by co-administration of Ad/AAV. | Q46866119 | ||
| Structures of the core oligosaccharide and O-units in the R- and SR-type lipopolysaccharides of reference strains of Pseudomonas aeruginosa O-serogroups. | Q46899684 | ||
| Impact of vector-priming on the immunogenicity of a live recombinant Salmonella enterica serovar typhi Ty21a vaccine expressing urease A and B from Helicobacter pylori in human volunteers | Q47586971 | ||
| Significant differences in type IV pilin allele distribution among Pseudomonas aeruginosa isolates from cystic fibrosis (CF) versus non-CF patients | Q47632976 | ||
| Prevention of invasive pseudomonas infection in burns with a new vaccine | Q47683913 | ||
| Clinical study to assess the immunogenicity and safety of a recombinant Pseudomonas aeruginosa OprF-OprI vaccine in burn patients | Q47796527 | ||
| Vaccination of cystic fibrosis patients against Pseudomonas aeruginosa reduces the proportion of patients infected and delays time to infection | Q47969223 | ||
| Attachment of the outer membrane lipoprotein (OprI) of Pseudomonas aeruginosa to the mucosal surfaces of the respiratory and digestive tract of chickens | Q48008222 | ||
| Immune responses in the airways by nasal vaccination with systemic boosting against Pseudomonas aeruginosa in chronic lung disease | Q48009346 | ||
| Systemic, nasal and oral live vaccines against Pseudomonas aeruginosa: a clinical trial of immunogenicity in lower airways of human volunteers. | Q50052368 | ||
| Immunization of young African green monkeys with OprF epitope 8-OprI-type A- and B-flagellin fusion proteins promotes the production of protective antibodies against nonmucoid Pseudomonas aeruginosa. | Q50583511 | ||
| Immunization of cystic fibrosis patients with a Pseudomonas aeruginosa O-polysaccharide-toxin A conjugate vaccine. | Q50921664 | ||
| Development of an anti-adhesive vaccine for Pseudomonas aeruginosa targeting the C-terminal region of the pilin structural protein. | Q50927945 | ||
| Mucosal vaccination with a recombinant OprF-I vaccine of Pseudomonas aeruginosa in healthy volunteers: comparison of a systemic vs. a mucosal booster schedule. | Q51665690 | ||
| Adenovirus 5 serotype vector-specific immunity and HIV-1 infection: a tale of T cells and antibodies. | Q51887043 | ||
| Vaccine strategies against Pseudomonas aeruginosa infection in the lung. | Q53973558 | ||
| In vitro and in vivo T cell responses in mice during bronchopulmonary infection with mucoid Pseudomonas aeruginosa. | Q54185707 | ||
| Outer membrane protein F (porin) preparation of Pseudomonas aeruginosa as a protective vaccine against heterologous immunotype strains in a burned mouse model. | Q54287067 | ||
| Opsonophagocytic killing antibody to Pseudomonas aeruginosa mucoid exopolysaccharide in older noncolonized patients with cystic fibrosis. | Q54400222 | ||
| IgG proteolytic activity of Pseudomonas aeruginosa in cystic fibrosis. | Q54452367 | ||
| The biological activity of a liposomal complete core lipopolysaccharide vaccine. | Q54546562 | ||
| The Pseudomonas aeruginosa outer membrane protein I vaccine: immunogenicity and safe administration in man. | Q54570980 | ||
| Safety and immunogenicity of a Pseudomonas aeruginosa outer membrane protein I vaccine in human volunteers. | Q54583590 | ||
| Genetic delivery of an anti-RSV antibody to protect against pulmonary infection with RSV | Q56929067 | ||
| The immune response to chronic Pseudomonas aeruginosa lung infection in cystic fibrosis patients is predominantly of the Th2 typeNote | Q63762098 | ||
| Infection of mouse bone marrow-derived dendritic cells with recombinant adenovirus vectors leads to presentation of encoded antigen by both MHC class I and class II molecules-potential benefits in vaccine design | Q64378294 | ||
| High efficiency adenovirus-mediated gene transfer to human dendritic cells | Q64382219 | ||
| Multivalent DNA vaccine protects mice against pulmonary infection caused by Pseudomonas aeruginosa | Q64449315 | ||
| Intratracheal immunization with pili protein protects against mortality associated with Pseudomonas aeruginosa pneumonia in mice | Q64449329 | ||
| Crystallographic analysis of the Pseudomonas aeruginosa strain K122-4 monomeric pilin reveals a conserved receptor-binding architecture | Q64449389 | ||
| The use of synthetic peptides in the design of a consensus sequence vaccine for Pseudomonas aeruginosa | Q64449880 | ||
| Comparison of type IV-pilin genes of Pseudomonas aeruginosa of various habitats has uncovered a novel unusual sequence | Q64450157 | ||
| Preparation and characterization of detoxified lipopolysaccharide-protein conjugates | Q64452136 | ||
| Controlled prospective trial of Pseudomonas aeruginosa vaccine in children with acute leukemia | Q67263567 | ||
| A human monoclonal antibody that protects mice against Pseudomonas-induced pneumonia | Q67298208 | ||
| Production and characterization of a human hyperimmune intravenous immunoglobulin against Pseudomonas aeruginosa and Klebsiella species | Q67986765 | ||
| Safety, pharmacokinetics, and functional activity of human anti-Pseudomonas aeruginosa monoclonal antibodies in septic and nonseptic patients | Q67998350 | ||
| Protection against mucoid Pseudomonas aeruginosa in rodent models of endobronchial infections | Q68347812 | ||
| Preliminary investigations of Pseudomonas aeruginosa vaccine in patients with leukemia and cystic fibrosis | Q68349957 | ||
| P433 | issue | 10 | |
| P304 | page(s) | 999-1011 | |
| P577 | publication date | 2011-10-01 | |
| P1433 | published in | Hum Vaccin | Q15755183 |
| P1476 | title | Recent developments for Pseudomonas vaccines | |
| P478 | volume | 7 |
| Q51532849 | 40 years on: have we finally got a vaccine for Pseudomonas aeruginosa? |
| Q40602729 | A DNA vaccine encoding VP22 of herpes simplex virus type I (HSV-1) and OprF confers enhanced protection from Pseudomonas aeruginosa in mice |
| Q64106013 | A Live Vaccine Delivering PcrV through the Type III Secretion System Protects against Pseudomonas aeruginosa |
| Q37687425 | A temporal examination of the planktonic and biofilm proteome of whole cell Pseudomonas aeruginosa PAO1 using quantitative mass spectrometry |
| Q34599868 | Adenovirus-based vaccine with epitopes incorporated in novel fiber sites to induce protective immunity against Pseudomonas aeruginosa |
| Q37620529 | Bioengineering a bacterial pathogen to assemble its own particulate vaccine capable of inducing cellular immunity |
| Q49052508 | Bovine serum albumin nanoparticle vaccine reduces lung pathology induced by live Pseudomonas aeruginosa infection in mice. |
| Q54260241 | Conserved OprF as a Selective Immunogen against Pseudomonas aeruginosa. |
| Q33763029 | Design of live attenuated bacterial vaccines based on D-glutamate auxotrophy. |
| Q27679901 | Discovery of an Allosteric Inhibitor Binding Site in 3-Oxo-acyl-ACP Reductase from Pseudomonas aeruginosa |
| Q40267074 | Efficacy comparison of adjuvants in PcrV vaccine against Pseudomonas aeruginosa pneumonia |
| Q36147444 | Genetic engineering of Francisella tularensis LVS for use as a novel live vaccine platform against Pseudomonas aeruginosa infections |
| Q61449788 | Genome-Based Approach Delivers Vaccine Candidates Against |
| Q35270721 | Immunogenicity comparison of conjugate vaccines composed of alginate and lipopolysaccharide of Pseudomonas aeruginosa bound to diphtheria toxoid |
| Q57489058 | Induction of Specific Humoral Immune Response in Mice against a Chimeric PilQ/PilA Protein |
| Q42206103 | Infection prevention and control guideline for cystic fibrosis: 2013 update |
| Q52673356 | Killed but metabolically active Pseudomonas aeruginosa-based vaccine induces protective humoral- and cell-mediated immunity against Pseudomonas aeruginosa pulmonary infections. |
| Q38941665 | Mannose-modified chitosan microspheres enhance OprF-OprI-mediated protection of mice against Pseudomonas aeruginosa infection via induction of mucosal immunity |
| Q64069605 | Mechanistic research holds promise for bacterial vaccines and phage therapies for |
| Q37478266 | Mucosal and systemic antibody responses to potential Pseudomonas aeruginosa vaccine protein antigens in young children with cystic fibrosis following colonization and infection |
| Q38243221 | New perspectives in the management of Pseudomonas aeruginosa infections |
| Q55222812 | PA0833 Is an OmpA C-Like Protein That Confers Protection Against Pseudomonas aeruginosa Infection. |
| Q57481190 | PLGA-encapsulation of the Pseudomonas aeruginosa PopB vaccine antigen improves Th17 responses and confers protection against experimental acute pneumonia |
| Q46475798 | Phytol has antibacterial property by inducing oxidative stress response in Pseudomonas aeruginosa |
| Q47415600 | Post-exposure immunization by capsid-modified AdC7 vector expressing Pseudomonas aeruginosa OprF clears P. aeruginosa respiratory infection |
| Q53701548 | Potential targets for next generation anti-microbial glycoconjugate vaccines. |
| Q33553646 | Protective effect of DNA vaccine encoding pseudomonas exotoxin A and PcrV against acute pulmonary P. aeruginosa Infection |
| Q26768365 | Pseudomonas aeruginosa ventilator-associated pneumonia management |
| Q38599969 | Pseudomonas aeruginosa: arsenal of resistance mechanisms, decades of changing resistance profiles, and future antimicrobial therapies |
| Q90213077 | Pushing beyond the Envelope: the Potential Roles of OprF in Pseudomonas aeruginosa Biofilm Formation and Pathogenicity |
| Q51053038 | RGD capsid modification enhances mucosal protective immunity of a non-human primate adenovirus vector expressing Pseudomonas aeruginosa OprF. |
| Q49908061 | Recent perspectives on the molecular basis of biofilm formation by Pseudomonas aeruginosa and approaches for treatment and biofilm dispersal. |
| Q99711236 | Repurposing Drugs, Ongoing Vaccine, and New Therapeutic Development Initiatives Against COVID-19 |
| Q41065563 | Salmonella Typhimurium strain expressing OprF-OprI protects mice against fatal infection by Pseudomonas aeruginosa |
| Q38210319 | Vaccine development and passive immunization for Pseudomonas aeruginosa in critically ill patients: a clinical update |
| Q40262035 | Vaccine strategies against cystic fibrosis pathogens |
| Q26852817 | Vaccines for Pseudomonas aeruginosa: a long and winding road |
| Q36583078 | X-ray Irradiated Vaccine Confers protection against Pneumonia caused by Pseudomonas aeruginosa |
Search more.